|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0169 USD | +0.93% |
|
-.--% | +3.68% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.3M 3.77M 3.51M 3.23M 6.06M 411M 41.67M 16.31M 204M 16.13M 15.79M 703M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.23M 5.47M 5.09M 4.68M 8.78M 595M 60.42M 23.65M 295M 23.39M 22.89M 1.02B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +0.93% | ||
| 3 months | +275.56% | ||
| 6 months | +275.56% | ||
| Current year | +3.68% |
| Current year | 0 | 0.02 | |
| 1 year | 0 | 0.05 | |
| 3 years | 0 | 0.06 | |
| 5 years | 0 | 0.1 | |
| 10 years | 0 | 0.28 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.93% | -.--% | - | - | 3.94M | ||
| -0.34% | +1.39% | +15.18% | +72.30% | 49.64B | ||
| +1.45% | +5.33% | +59.98% | +121.15% | 36.54B | ||
| +1.79% | +3.91% | -6.58% | +25.15% | 12.22B | ||
| +1.06% | -1.45% | +11.57% | +75.56% | 11.48B | ||
| +1.91% | +1.16% | +31.33% | +131.86% | 9.04B | ||
| +3.39% | +3.87% | +50.44% | -3.98% | 6.94B | ||
| -0.51% | -0.85% | +11.77% | +33.26% | 6.74B | ||
| +0.61% | -0.09% | +1.85% | +178.99% | 6.45B | ||
| -1.32% | -6.80% | -33.10% | -2.26% | 5.42B | ||
| Average | +0.89% | -0.64% | +15.83% | +70.23% | 16.05B | |
| Weighted average by Cap. | +0.73% | +0.49% | +24.52% | +81.14% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.55M 3.12M 2.9M 2.67M 5.01M 339M 34.44M 13.48M 168M 13.34M 13.05M 581M | 1.19M 830K 729K 679K 624K 1.17M 79.32M 8.05M 3.15M 39.34M 3.12M 3.05M 136M |
| Net income | -5.8M -4.05M -3.55M -3.31M -3.04M -5.7M -387M -39.24M -15.36M -192M -15.19M -14.86M -662M | -5.94M -4.15M -3.64M -3.39M -3.12M -5.84M -396M -40.22M -15.74M -197M -15.57M -15.24M -679M |
| Net Debt | 759K 530K 465K 433K 398K 746K 50.59M 5.13M 2.01M 25.09M 1.99M 1.95M 86.69M | 2.77M 1.93M 1.7M 1.58M 1.45M 2.73M 185M 18.75M 7.34M 91.64M 7.26M 7.1M 317M |
Employees
43
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
- ARUXF Stock
Select your edition
All financial news and data tailored to specific country editions
















